StudyFinder
A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis
Status: Recruiting
To evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)
Sex: Male or Female
Age Group: 18 years and over
Inclusion Criteria:
• newly diagnosed or relapse of granulomatosis and induction treatment with cyclophosphamide or rituximab is needed
• see link to clinicaltrials.gov for complete Inclusion criteria
Exclusion Criteria:
• any other known multisystem autoimmune disease
• had a kidney transplant
• cancer in the past 5 years
• any significant cardiovascular disease
• taking an oral daily dose of a glucocorticoid of more than 10 mg prednisone equivalent for more than 6 weeks
• see link to clinicaltrials.gov for complete Exclusion criteria
Conditions:
Immune Diseases
Keywords:
Clinics and Surgery Center (CSC), Antineutrophil Cytoplasmic Antibody-associated Vasculitis, Vasculitis
Study Contact: Madeline Moore - moor1449@umn.edu
Principal Investigator: Sahar Koubar
Phase: PHASE4
IRB Number: STUDY00020711
See this study on ClinicalTrials.gov